Needham analyst Ryan MacDonald has maintained their bullish stance on HNGE stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ryan MacDonald has given his Buy rating due to a combination of factors that highlight Hinge Health’s attractive growth and valuation profile. His channel checks during the key selling season suggest the company is solidifying its leadership position in the digital musculoskeletal (MSK) market, which he believes sets up strong momentum into 2026. Drawing on detailed cohort analysis, he projects that revenue in FY26 could reach about $750 million, materially above current internal and street forecasts. At that level, he expects Hinge Health could again meet or exceed the “Rule of 50,” signaling a compelling balance of growth and profitability.
MacDonald also points out that the stock currently trades at a modest multiple of roughly 5.7 times his FY26 revenue estimate, which he views as undemanding given the company’s growth trajectory. He sees several potential catalysts that could justify a higher valuation, including increased adoption of the HingeSelect offering and the opening of a new Medicare-focused opportunity. Together, these drivers underpin his view that there is meaningful upside for both revenue and the stock’s multiple over the next couple of years, supporting his Buy recommendation.
According to TipRanks, MacDonald is an analyst with an average return of -4.1% and a 39.76% success rate. MacDonald covers the Technology sector, focusing on stocks such as Liveperson, Yext, and Docebo.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $60.00 price target.